Pfizer: targets raised for 2024
(CercleFinance.com) - On its quarterly earnings call, Pfizer raised its target ranges for FY 2024, now anticipating adjusted EPS of $2.
45 to $2.65 and revenues of $59.5bn to $62.5bn.
The pharmaceutical giant's Q2 adjusted EPS fell by 11% to $0.60, despite revenues growing by 2% to nearly $13.3bn (+3% in operational terms, of which +14% excluding Covid-19 products).
In addition, Pfizer says it is on track to achieve at least $4bn in net cost savings by the year-end, as part of its previously announced cost realignment program.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
45 to $2.65 and revenues of $59.5bn to $62.5bn.
The pharmaceutical giant's Q2 adjusted EPS fell by 11% to $0.60, despite revenues growing by 2% to nearly $13.3bn (+3% in operational terms, of which +14% excluding Covid-19 products).
In addition, Pfizer says it is on track to achieve at least $4bn in net cost savings by the year-end, as part of its previously announced cost realignment program.
Copyright (c) 2024 CercleFinance.com. All rights reserved.